NEW YORK CITY, NY / ACCESS Newswire / May 20, 2026 / Emerging Growth Research today announced the release of its Q1:26 Quarterly Update Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), upgrading the Company to a

<p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 20, 2026 / </strong>Emerging Growth Research today announced the release of its Q1:26 Quarterly Update Report on SBC Medical Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SBC">SBC</a>), upgrading the Company to a Buy rating and increasing its 12-month price target to $10.00 from $9.00, representing significant potential upside from the Company's recent share price of $2.89 as of May 19, 2026.</p><p>The Quarterly Update highlights SBC's expectation for a return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, and long-term global growth strategy.</p><p><strong>Key Highlights from the Q1:26 Quarterly Update:</strong></p><ul><li><p>Return to Growth Expected in 2026: Emerging Growth Research believes the impact of SBC's early-2025 franchise fee restructuring is now largely absorbed, positioning the Company for renewed revenue growth beginning in 2026.</p></li><li><p>Underlying Business Trends Remain Strong: Q1:26 same-clinic sales increased +6% year-over-year, while customer growth rose +10% year-over-year to approximately 6.7 million annual visits with a 72% repeat rate.</p></li><li><p>Sequential Improvement in Financial Results: While Q1:26 revenue declined 9% year-over-year to $43.1 million, revenue increased +9% sequentially from Q4:25. Operating profit also increased +38% sequentially.</p></li><li><p>Significant Cash Position Supports Expansion: SBC ended Q1:26 with approximately $167 million in cash and only modest debt levels, leaving the Company with a strong net cash position relative to its market capitalization.</p></li><li><p>Continued Clinic Expansion: SBC expanded its clinic network to 284 locations, up +13% year-over-year, as management continues to pursue its long-term objective of reaching 1,000 clinics globally over the next nine years.</p></li><li><p>International Expansion and New Growth Initiatives: The Company continues to pursue strategic M&A opportunities in Japan, Southeast Asia, and the United States while also investing in AI-driven operational initiatives and longevity-focused wellness services.</p></li><li><p>Improved Trading Liquidity: Emerging Growth Research noted that the founder's recent partial share sale increased public float and trading liquidity while maintaining strong founder alignment with shareholders.</p></li><li><p>Attractive Valuation: Emerging Growth Research believes SBC shares remain materially undervalued relative to the Company's long-term earnings potential, strong operating margins, and substantial net cash position.</p></li></ul><p><strong>For a copy of the full Q1:26 Quarterly Update Report, please visit:</strong></p><p><a rel="nofollow" href="https://pr.report/lpxq">https://storage.googleapis.com/accesswire/media/1168563/sbcq126-quarterly-update-052026.pdf</a></p><p>or</p><p><a rel="nofollow" href="https://pr.report/lpxr">https://www.emerginggrowth.com/profile/sbc/</a> (on the right side of the page as you scroll down)</p><p><strong>About SBC Medical Group Holdings, Inc.</strong></p><p>SBC Medical Group Holdings, Inc. provides management services to cosmetic treatment centers through a franchise model operating across Japan, Southeast Asia, and the United States. The Company operates a diversified portfolio of cosmetic, dermatology, and wellness-focused brands and continues to expand through both organic growth and strategic acquisitions.</p><p><strong>About Emerging Growth Research</strong></p><p>Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging growth companies.</p><p><strong>Contact:</strong></p><p>Emerging Growth Research<br/><a rel="nofollow" href="mailto:Research@EmergingGrowth.com">Research@EmergingGrowth.com</a><br/><a rel="nofollow" href="https://pr.report/lpxs">https://www.emerginggrowth.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements concerning business operations, financial performance, growth initiatives, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.</p><a href="https://app.accessnewswire.com/imagelibrary/6cf56c02-6e52-440e-9d7c-1a19bf399ca4/egr-logo-for-accesswire.png" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/6cf56c02-6e52-440e-9d7c-1a19bf399ca4/1168563/egr-logo-for-accesswire.png" style="width:720px;text-align:center;margin:0.9em auto;"></a><div> </div><p><strong>SOURCE</strong>: SBC Medical Group Holdings Incorporated</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-q1-26-quarterly-update-on-sbc-medic-1168563'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1168563" width="0" height="0"/>

Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00

SBC Medical Group Upgraded to Buy with $10 Target

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK CITY, NY / ACCESS Newswire / May 20, 2026 / Emerging Growth Research today announced the release of its Q1:26 Quarterly Update Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), upgrading the Company to a</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Emerging Growth Research has upgraded SBC Medical Group to a Buy rating, raising its 12-month price target to $10 from $9. The report indicates a strong revenue growth outlook for 2026, backed by solid cash reserves and ongoing clinic expansion strategies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>SBC Medical upgraded to Buy with a $10 price target.</li><li>Revenue growth expected in 2026 after past pricing headwinds.</li><li>Q1:26 same-clinic sales rose 6% year-over-year.</li><li>Strong cash position of $167 million supports expansion plans.</li><li>Clinic network expanded 13% year-over-year to 284 locations.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>SBC Medical Group Holdings, Inc. (SBC)</strong>: Upgraded to Buy; promising growth with new initiatives in clinics.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The category fits as &#039;Corporate Developments&#039; due to SBC’s strategic initiatives and financial updates indicating future growth potential.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>SBC&#039;s share price could rise significantly from its current $2.89 level.</li><li>Expected revenue growth in 2026 may attract more institutional investors.</li><li>Expansion into new international markets could further boost earnings.</li><li>Strong financial position allows for strategic investments and growth.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Current share price is $2.89 as of May 19, 2026.</li><li>Q1:26 revenue decreased 9% year-over-year to $43.1 million.</li><li>SBC reported a cash position of $167 million with low debt.</li><li>The clinic network grew by 13% to 284 locations.</li><li>12-month price target raised from $9 to $10.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying SBC as it approaches a price target of $10 over the next 12 months.</p>
  </section>
</section>


<p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 20, 2026 / </strong>Emerging Growth Research today announced the release of its Q1:26 Quarterly Update Report on SBC Medical Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SBC">SBC</a>), upgrading the Company to a Buy rating and increasing its 12-month price target to $10.00 from $9.00, representing significant potential upside from the Company's recent share price of $2.89 as of May 19, 2026.</p><p>The Quarterly Update highlights SBC's expectation for a return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, and long-term global growth strategy.</p><p><strong>Key Highlights from the Q1:26 Quarterly Update:</strong></p><ul><li><p>Return to Growth Expected in 2026: Emerging Growth Research believes the impact of SBC's early-2025 franchise fee restructuring is now largely absorbed, positioning the Company for renewed revenue growth beginning in 2026.</p></li><li><p>Underlying Business Trends Remain Strong: Q1:26 same-clinic sales increased +6% year-over-year, while customer growth rose +10% year-over-year to approximately 6.7 million annual visits with a 72% repeat rate.</p></li><li><p>Sequential Improvement in Financial Results: While Q1:26 revenue declined 9% year-over-year to $43.1 million, revenue increased +9% sequentially from Q4:25. Operating profit also increased +38% sequentially.</p></li><li><p>Significant Cash Position Supports Expansion: SBC ended Q1:26 with approximately $167 million in cash and only modest debt levels, leaving the Company with a strong net cash position relative to its market capitalization.</p></li><li><p>Continued Clinic Expansion: SBC expanded its clinic network to 284 locations, up +13% year-over-year, as management continues to pursue its long-term objective of reaching 1,000 clinics globally over the next nine years.</p></li><li><p>International Expansion and New Growth Initiatives: The Company continues to pursue strategic M&A opportunities in Japan, Southeast Asia, and the United States while also investing in AI-driven operational initiatives and longevity-focused wellness services.</p></li><li><p>Improved Trading Liquidity: Emerging Growth Research noted that the founder's recent partial share sale increased public float and trading liquidity while maintaining strong founder alignment with shareholders.</p></li><li><p>Attractive Valuation: Emerging Growth Research believes SBC shares remain materially undervalued relative to the Company's long-term earnings potential, strong operating margins, and substantial net cash position.</p></li></ul><p><strong>For a copy of the full Q1:26 Quarterly Update Report, please visit:</strong></p><p><a rel="nofollow" href="https://pr.report/lpxq">https://storage.googleapis.com/accesswire/media/1168563/sbcq126-quarterly-update-052026.pdf</a></p><p>or</p><p><a rel="nofollow" href="https://pr.report/lpxr">https://www.emerginggrowth.com/profile/sbc/</a> (on the right side of the page as you scroll down)</p><p><strong>About SBC Medical Group Holdings, Inc.</strong></p><p>SBC Medical Group Holdings, Inc. provides management services to cosmetic treatment centers through a franchise model operating across Japan, Southeast Asia, and the United States. The Company operates a diversified portfolio of cosmetic, dermatology, and wellness-focused brands and continues to expand through both organic growth and strategic acquisitions.</p><p><strong>About Emerging Growth Research</strong></p><p>Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging growth companies.</p><p><strong>Contact:</strong></p><p>Emerging Growth Research<br/><a rel="nofollow" href="mailto:Research@EmergingGrowth.com">Research@EmergingGrowth.com</a><br/><a rel="nofollow" href="https://pr.report/lpxs">https://www.emerginggrowth.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements concerning business operations, financial performance, growth initiatives, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.</p><a href="https://app.accessnewswire.com/imagelibrary/6cf56c02-6e52-440e-9d7c-1a19bf399ca4/egr-logo-for-accesswire.png" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/6cf56c02-6e52-440e-9d7c-1a19bf399ca4/1168563/egr-logo-for-accesswire.png" style="width:720px;text-align:center;margin:0.9em auto;"></a><div> </div><p><strong>SOURCE</strong>: SBC Medical Group Holdings Incorporated</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-q1-26-quarterly-update-on-sbc-medic-1168563'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1168563" width="0" height="0"/>

Emerging Growth Research has upgraded SBC Medical Group to a Buy rating, raising its 12-month price target to $10 from $9. The report indicates a strong revenue growth outlook for 2026, backed by solid cash reserves and ongoing clinic expansion strategies.

Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News